📰 Valuating News
Page 3 - Valuating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valuating. Real-time updates on events, politics, business and more.
May 25, 2023
Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem™ to Treat... | May 25, 2023
May 25, 2023
83% of glioblastoma patients remain alive after 14 months on study, a percentage well above what is expected for the enrolled population of chemotherapy refractory patients Survival data will
May 23, 2023
Rain Oncology Inc. announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in patients with dedifferentiated liposarcoma , did... | May 23, 2023
May 18, 2023
New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel will be presented at the 2023 American Society of Clinical Oncology ... | May 18, 2023
May 17, 2023
By Chris Wack Ultragenyx Pharmaceutical said Wednesday that the U.S. Food and Drug Administration has reviewed and agreed to a protocol amendment to a Phase 1/2 study evaluating the safety and... | May 17, 2023
May 17, 2023
In a significant step towards indigenising critical warfighting equipment, India is evaluating proposals from American and French firms for its Made in India aircraft including the LCA Mark 2 and the Advanced Medium Combat Aircraft.
May 16, 2023
Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023National educational campaign launched to further... | May 16, 2023
May 16, 2023
SAN DIEGO - Neurocrine Biosciences, Inc. today announced findings from a post hoc analysis of two long-term studies of INGREZZA capsules evaluating global tardive dyskinesia improvement and... | May 16, 2023
May 15, 2023
SAN DIEGO, May 15, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. today announced findings from a post hoc analysis of two long-term studies of INGREZZA® capsules evaluating global tardive... | May 15, 2023
May 15, 2023
Company on track to complete enrollment in ongoing pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 by year end 2023 ... | May 15, 2023